RT Journal Article
SR Electronic
T1 Dynamics of SARS-CoV-2 with Waning Immunity in the UK Population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.24.20157982
DO 10.1101/2020.07.24.20157982
A1 Crellen, Thomas
A1 Pi, Li
A1 Davis, Emma L.
A1 Pollington, Timothy M.
A1 Lucas, Tim C. D.
A1 Ayabina, Diepreye
A1 Borlase, Anna
A1 Toor, Jaspreet
A1 Prem, Kiesha
A1 Medley, Graham F.
A1 Klepac, Petra
A1 Hollingsworth, T. Déirdre
YR 2021
UL http://medrxiv.org/content/early/2021/02/04/2020.07.24.20157982.abstract
AB The dynamics of immunity are crucial to understanding the long-term patterns of the SARS-CoV-2 pandemic. Several cases of reinfection with SARS-CoV-2 have been documented 48–142 days after the initial infection and immunity to seasonal circulating coronaviruses is estimated to be shorter than one year. Using an age-structured, deterministic model, we explore potential immunity dynamics using contact data from the UK population. In the scenario where immunity to SARS-CoV-2 lasts an average of three months for non-hospitalised individuals, a year for hospitalised individuals, and the effective reproduction number after lockdown ends is 1.2 (our worst case scenario), we find that the secondary peak occurs in winter 2020 with a daily maximum of 387,000 infectious individuals and 125,000 daily new cases; three-fold greater than in a scenario with permanent immunity. Our models suggests that longitudinal serological surveys to determine if immunity in the population is waning will be most informative when sampling takes place from the end of the lockdown in June until autumn 2020. After this period, the proportion of the population with antibodies to SARS-CoV-2 is expected to increase due to the secondary wave. Overall, our analysis presents considerations for policy makers on the longer term dynamics of SARS-CoV-2 in the UK and suggests that strategies designed to achieve herd immunity may lead to repeated waves of infection as immunity to reinfection is not permanent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTC is funded by a Sir Henry Wellcome Postdoctoral Fellowship from the Wellcome Trust (reference 215919/Z/19/Z). ELD, TCDL, DA, AB, TMP and TDH gratefully acknowledge funding of the NTD Modelling Consortium by the Bill & Melinda Gates Foundation (BMGF) (grant number OPP1184344). Views, opinions, assumptions or any other information set out in this article should not be attributed to BMGF or any person connected with them. TMP's PhD was supported by the Engineering & Physical Sciences Research Council, Medical Research Council and University of Warwick (grant number EP/L015374/1). All funders had no role in the study design, collection, analysis, interpretation of data, writing the report, or decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis is a modelling study and does not use primary data. Open access code to reproduce the analysis is provided. https://github.com/tc13/covid-19-immunity